Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SJCARB7H3_41BBL |
| Synonyms | |
| Therapy Description |
Limited information is currently available on SJCARB7H3_41BBL, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD276 (B7H3) (Mar 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SJCARB7H3_41BBL | SJCAR-B7H3_41BBL|SJCARB7H3-41BBL | CD276 Immune Cell Therapy 12 | Limited information is currently available on SJCARB7H3_41BBL, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD276 (B7H3) (Mar 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07428993 | Phase II | SJCARB7H3_41BBL Cyclophosphamide + Fludarabine Mesna | Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma | Not yet recruiting | USA | 0 |